Mentioned:
LLY +0.65% NVO
Eli Lilly is on the verge of a potential major new drug approval. And now, they’re pouring more than a billion dollars into preparing to launch it in America.
What’s happening:
- Eli Lilly (NYSE: LLY) has accumulated $1.5B USD of pre-launch inventory of their weight loss pill orforglipron according to new filings made with the United States Securities and Exchange Commission
Why it matters:
- Eli Lilly has completed Phase III clinical trials for using orforglipron to treat obesity as a once daily weight loss pill and is currently awaiting regulatory approval from the United States Food and Drug Administration
Going deeper:
- Eli Lilly’s $1.5B USD of pre-launch inventory for orforglipron is an increase of $1B USD from their previous investment in inventory
- Novo Nordisk (NYSE: NVO) just recently made major waves on Wall Street when they won regulatory approval from the United States Food and Drug Administration for their Wegovy GLP-1 pill for weight loss
